Marketed in 67 countries across Europe, the Americas, and the Asia-Pacific region, Xarelto is a globally distributed brand of rivaroxaban, classified as an anticoagulant and a factor Xa inhibitor. It is among the more internationally familiar oral anticoagulant brands, which makes it a frequent point of reference for travellers and expatriates trying to identify equivalent therapy abroad.
Rivaroxaban is prescribed in the context of stroke prevention and the management of cerebrovascular events, where suppression of clot formation through factor Xa inhibition is part of the therapeutic approach. The structured indication block further down this page lists the registered uses recognised by the regulatory authorities in each of the markets where Xarelto is sold, and these can vary from one jurisdiction to another.
Because Xarelto carries marketing authorisation in so many countries — including Canada, China, Australia, Belgium, and Chile among others — readers crossing borders often encounter the same brand abroad. Packaging, prescription pathways, and even the specific approved indications can differ between markets, however, and a pharmacist in the destination country is best placed to confirm whether a locally stocked rivaroxaban product corresponds to what the patient was prescribed at home.
Other oral anticoagulants in the factor Xa inhibitor class, as well as anticoagulants working through different mechanisms, are sold internationally under separate molecules and brand names. They are not freely interchangeable, and switching between anticoagulants is a clinical decision rather than a pharmacy-counter one. Anyone taking Xarelto, identifying a local equivalent, or considering any change to anticoagulant therapy should speak with a healthcare provider before acting on it.
June 2017
Bayer AG
51368 Leverkusen
Germany
EU/1/08/472/040
No special requirements for disposal.
Date of first authorisation: 30 September 2008
Date of latest renewal: 22 May 2013
Xarelto is prescribed in the context of stroke prevention and the management of cerebrovascular events. As a factor Xa inhibitor within the broader anticoagulant class, it acts on a specific step in the clotting cascade, which is the basis for its role in reducing the risk of clot-related events. The structured indication list below this introduction details the registered uses recognised by national regulators in the markets where Xarelto is authorised.
Xarelto contains rivaroxaban, an oral anticoagulant that works as a direct factor Xa inhibitor. Rivaroxaban is the same molecule whether sold under the Xarelto brand or, in markets where regulatory pathways allow, under a generic name. The same active ingredient circulates internationally under different commercial labels depending on the country and the manufacturer.
Xarelto is registered in 67 countries, spanning Europe, North and South America, the Asia-Pacific region, and beyond. Examples include Canada, China, Australia, Denmark, Chile, the Czech Republic, and Colombia. If your country is not represented in this list, a local pharmacist can usually confirm whether rivaroxaban is available in that market under the Xarelto brand or another commercial name.
Rivaroxaban is sold under additional brand names in some markets, particularly where multiple manufacturers are authorised to produce it. Other oral anticoagulants within the factor Xa inhibitor class also exist internationally, alongside anticoagulants that work through different mechanisms — none of which are freely interchangeable. To identify a locally available rivaroxaban product, search the active ingredient on Pill2Trip or speak with a pharmacist.
Yes. Xarelto is a prescription medication, and anticoagulant therapy is calibrated closely to a patient's individual circumstances, concurrent medications, and clinical history. This is particularly relevant for travellers and people relocating, since prescription rules, available brands, and approved indications differ between countries. Any decision to start, stop, switch, or substitute rivaroxaban should be made together with a healthcare provider familiar with the patient.
